Emerging drugs for the treatment of hypercholesterolemia

References

• Catapano AL, Graham I, De Backer G, et al. ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2016;37:2999–3058.
   PubMed Web of Science ®Google Scholar
• Graham IM, Catapano AL, Wong ND. Current guidelines on prevention with a focus on dyslipidemias. Cardiovasc Diagn Ther. 2017;7:S4–S10.
   PubMed Web of Science ®Google Scholar
• Nayor M, Vasan RS. Recent update to the US cholesterol treatment guidelines: a comparison with international guidelines. Circulation. 2016;133(18):1795–1806.
   PubMed Web of Science ®Google Scholar
• Grundy SM, Stone NJ, Bailey AL, et al. AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. J Am Coll Cardiol. 2018. DOI:10.1016/j.jacc.2018.11.003.
   Google Scholar
• Reiner Ž. Statins in the primary prevention of cardiovascular disease. Nat Rev Cardiol. 2013;10(8):453–464.
   PubMed Web of Science ®Google Scholar
• Bove M, Fogacci F, Cicero AFG. Pharmacokinetic drug evaluation of ezetimibe + simvastatin for the treatment of hypercholesterolemia. Expert Opin Drug Metab Toxicol. 2017;13(10):1099–1104.
   PubMed Web of Science ®Google Scholar
• Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387–2397.
   PubMed Web of Science ®Google Scholar
• Murphy SA, Cannon CP, Blazing MA, et al. Reduction in total cardiovascular events with ezetimibe/simvastatin post-acute coronary syndrome: the IMPROVE-IT trial. J Am Coll Cardiol. 2016;67(4):353–361.
   PubMed Web of Science ®Google Scholar
• Norata GD, Tavori H, Pirillo A, et al. Biology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering. Cardiovasc Res. 2016;112(1):429–442.
   PubMed Web of Science ®Google Scholar
• Reiner Ž. PCSK9 inhibitors–past, present and future. Expert Opin Drug Metab Toxicol. 2015;11(10):1517–1521.
   PubMed Web of Science ®Google Scholar
• Reiner Ž. PCSK9 inhibitors in clinical practice: expectations and reality. Atherosclerosis. 2018;270:187–188.
   PubMed Web of Science ®Google Scholar
• Pećin I, Hartgers ML, Hovingh GK, et al. Prevention of cardiovascular disease in patients with familial hypercholesterolaemia: the role of PCSK9 inhibitors. Eur J Prev Cardiol. 2017;24(13):1383–1401.
   PubMed Web of Science ®Google Scholar
• Giugliano RP, Sabatine MS. Are PCSK9 inhibitors the next breakthrough in the cardiovascular field? J Am Coll Cardiol. 2015;65(24):2638–2651.
   PubMed Web of Science ®Google Scholar
• Dadu RT, Ballantyne CM. Lipid lowering with PCSK9 inhibitors. Nat Rev Cardiol. 2014;11(10):563–575.
   PubMed Web of Science ®Google Scholar
• Cicero AF, Tartagni E, Ertek S. Safety and tolerability of injectable lipid-lowering drugs: a review of available clinical data. Expert Opin Drug Saf. 2014;13:1023–1030.
   PubMed Web of Science ®Google Scholar
• Zhang XL, Zhu QQ, Zhu L, et al. Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials. BMC Med. 2015;13:123.
   PubMed Web of Science ®Google Scholar
• Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American college of cardiology task force on clinical expert consensus documents. J Am Coll Cardiol. 2016;68:92–125.
   PubMed Web of Science ®Google Scholar
• Stoekenbroek RM, Kastelein JJP. Proprotein convertase subtilisin/kexin type 9: from genetics to clinical trials. Curr Opin Cardiol. 2018;33(3):269–275.
   PubMed Web of Science ®Google Scholar
• Karagiannis AD, Liu M, Toth PP, et al. Pleiotropic anti-atherosclerotic effects of pcsk9 inhibitorsfrom molecular biology to clinical translation. Curr Atheroscler Rep. 2018;20(4):20.
   PubMed Web of Science ®Google Scholar
• Cicero AF, Bove M, Borghi C. Pharmacokinetics, pharmacodynamics and clinical efficacy of non-statin treatments for hypercholesterolemia. Expert Opin Drug Metab Toxicol. 2018;14(1):9–15.
   PubMed Web of Science ®Google Scholar
• Reiner Ž. Resistance and intolerance to statins. Nutr Metab Cardiovasc Dis. 2014;24(10):1057–1066.
   PubMed Web of Science ®Google Scholar
• Ferrari R, Aguiar C, Alegria E, et al. Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia. Eur Heart J Suppl. 2016 Apr 12;18(Suppl C):C2–C12.
   PubMed Web of Science ®Google Scholar
• Emerging Risk Factors Collaboration, Erqou S, Kaptoge S, Perry PL, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMAR 2009;302(4):412–423.
   PubMed Web of Science ®Google Scholar
• Capoulade R, Chan KL, Yeang C, et al. Oxidized phospholipids, lipoprotein(a), and progression of calcific aortic valve stenosis. J Am Coll Cardiol. 2015;66:1236–1246.
   PubMed Web of Science ®Google Scholar
• Graham MJ, Viney N, Crooke RM, et al. Antisense inhibition of apolipoprotein (a) to lower plasma lipoprotein (a) levels in humans. J Lipid Res. 2016;57(3):340–351.
   PubMed Web of Science ®Google Scholar
• Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267–1278.
   PubMed Web of Science ®Google Scholar
• Naci H, Brugts J, Ades T. Comparative tolerability and harms of individual statins: a study-level network meta-analysis of 246 955 participants from 135 randomized, controlled trials. Circ Cardiovasc Qual Outcomes. 2013;6(4):390–399.
   PubMed Web of Science ®Google Scholar
• Rosenson RS, Baker SK, Jacobson TA, et al. An assessment by the statin muscle safety task force: 2014 update. J Clin Lipidol. 2014;8:S58–71.
   PubMed Web of Science ®Google Scholar
• Guyton JR, Bays HE, Grundy SM, et al. An assessment by the statin intolerance panel: 2014 update. J Clin Lipidol. 2014;8:S72–81.
   PubMed Web of Science ®Google Scholar
• Ahmad Z. Statin intolerance. Am J Cardiol. 2014;113:1765–1771.
   PubMed Web of Science ®Google Scholar
• Patel J, Martin SS, Banach M. Expert opinion: the therapeutic challenges faced by statin intolerance. Expert Opin Pharmacother. 2016;17:1497–1507.
   PubMed Web of Science ®Google Scholar
• Banach M, Patti AM, Giglio RV, et al. International Lipid Expert Panel (ILEP). The role of nutraceuticals in statin intolerant patients. J Am Coll Cardiol. 2018;72(1):96–118.
   PubMed Web of Science ®Google Scholar
• Šimić I, Reiner Ž. Adverse effects of statins - myths and reality. Curr Pharm Des. 2015;21(9):1220–1226.
   PubMed Web of Science ®Google Scholar
• Jakob T, Nordmann AJ, Schandelmaier S, et al. Fibrates for primary prevention of cardiovascular disease events. Cochrane Database Syst Rev. 2016;11:CD009753.
   PubMedGoogle Scholar
• Saha SA, Kizhakepunnur LG, Bahekar A, et al. The role of fibrates in the prevention of cardiovascular disease–a pooled meta-analysis of long-term randomized placebo-controlled clinical trials. Am Heart J. 2007;154(5):943–953.
   PubMed Web of Science ®Google Scholar
• Davidson MH, McGarry T, Bettis R, et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol. 2002;40:2125–2134.
   PubMed Web of Science ®Google Scholar
• Liu C, Liu Q, Xiao X. Effectiveness and safety of combinational therapy compared with intensified statin monotherapy in patients with coronary heart disease. Exp Ther Med. 2018;15(6):4683–4688.
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Hoogeveen RC, Raya JL, et al. Efficacy, safety and effect on biomarkers related to cholesterol and lipoprotein metabolism of rosuvastatin 10 or 20 mg plus ezetimibe 10 mg vs. simvastatin 40 or 80 mg plus ezetimibe 10 mg in high-risk patients: results of the GRAVITY randomized study. Atherosclerosis. 2014;232(1):86–93.
   PubMed Web of Science ®Google Scholar
• Ouchi Y. Ezetimibe in prevention of cerebro- and cardiovascular events in middle- to high-risk, elderly (75 years old or over) patients with elevated LDL-cholesterol: a multicenter, randomized, controlled, open-label trial. Chicago, IL: AHA; 2018
   Google Scholar
• Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;377(8):787–788.
   PubMedGoogle Scholar
• Farnier M, Gaudet D, Valcheva V, et al. Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: pooled analysis of eight ODYSSEY Phase 3 clinical program trials. Int J Cardiol. 2016;223:750–757.
   PubMed Web of Science ®Google Scholar
• Bonaca MP, Nault P, Giugliano RP, et al. Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER trial (Further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk). Circulation. 2018;137:338–350.
   PubMed Web of Science ®Google Scholar
• Szarek M, White HD, Schwartz GG, et al. Alirocumab reduces total nonfatal cardiovascular and fatal events in the odyssey outcomes trial. J Am Coll Cardiol. 2018. DOI:10.1016/j.jacc.2018.10.039.
   PubMed Web of Science ®Google Scholar
• Tall AR, Rader DJ. Trials and tribulations of cetp inhibitors. Circ Res. 2018;122(1):106–112.
   PubMed Web of Science ®Google Scholar
• Borghi C, Cicero AF. Pharmacokinetic drug evaluation of anacetrapib for the treatment of dyslipidemia. Expert Opin Drug Metab Toxicol. 2017;13:205–209.
   PubMed Web of Science ®Google Scholar
• Bowman L, Hopewell JC, Chen, F, et al. HPS3/TIMI55–REVEAL Collaborative Group. Effects of anacetrapib in patients with atherosclerotic vascular disease. N Engl J Med. 2017;377:1217.
   PubMed Web of Science ®Google Scholar
• Panta R, Dahal K, Kunwar S. Efficacy and safety of mipomersen in treatment of dyslipidemia: a meta-analysis of randomized controlled trials. J Clin Lipidol. 2015;9:217–225.
   PubMed Web of Science ®Google Scholar
• Cuchel M, Meagher EA, Du Toit Theron H, et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet. 2013;381:40–46.
   PubMed Web of Science ®Google Scholar
• Raal FJ, Santos RD, Blom DJ, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375(9719):998–1006.
   PubMed Web of Science ®Google Scholar
• Landlinger C, Pouwer MG, Juno C, et al. The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice. Eur Heart J. 2017;38:2499–2507.
   PubMed Web of Science ®Google Scholar
• Weisshaar S, Zeitlinger M. Vaccines targeting PCSK9: a promising alternative to passive immunization with monoclonal antibodies in the management of hyperlipidaemia? Drugs. 2018;78(8):799–808.
   PubMed Web of Science ®Google Scholar
• Miller M, Stone NJ, Ballantyne C, et al. Triglycerides and cardiovascular disease: a scientific statement from the American hear tassociation. Circulation. 2011;123(20):2292–2333.
   PubMed Web of Science ®Google Scholar
• Reiner Z. Hypertriglyceridaemia and risk of coronary artery disease. Nat Rev Cardiol. 2017;14:401–411.
   PubMed Web of Science ®Google Scholar
• Reiner Ž. Triglyceride-rich lipoproteins and novel targets for anti-atherosclerotic therapy. Korean Circ J. 2018;48(12):1097–1119.
   PubMed Web of Science ®Google Scholar
• Penson P, McGowan M, Banach M. Evaluating bempedoic acid for the treatment of hyperlipidaemia. Expet Opin Invest Drugs. 2017;26(2):251–259.
   PubMed Web of Science ®Google Scholar
• Gutierrez MJ, Rosenberg NL, Macdougall DE, et al. Efficacy and safety of ETC-1002, a novel investigational low-density lipoprotein-cholesterol-lowering therapy for the treatment of patients with hypercholesterolemia and type 2 diabetes mellitus, arterioscler. Thromb Vasc Biol. 2014;34:676–683.
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, McKenney JM, MacDougall DE, et al. Effect of ETC-1002 on serum low-density lipoprotein cholesterol in hypercholesterolemic patients receiving statin therapy. Am J Cardiol. 2016;117:1928–1933.
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Banach M, Mancini GBJ, et al. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: a randomized, placebo-controlled study. Atherosclerosis. 2018;S0021-9150(18)30309–5. DOI:10.1016/j.atherosclerosis.2018.
   Google Scholar
• Gaudet D, Alexander VJ, Baker BF, et al. Antisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemia. N Engl J Med. 2015;373(5):438–447.
   PubMed Web of Science ®Google Scholar
• Gouni-Berthold I, Alexander V, Digenio A, et al. Apolipoprotein C-III inhibition with volanesorsen in patients with hypertriglyceridemia (COMPASS): a randomized, double-blind, placebo-controlled trial. J Clin Lipidol. 2017;11(3):794–795.
   Google Scholar
• Arca M, Hsieh A, Soran H, et al. The effect of volanesorsen treatment on the burden associated with familial chylomicronemia syndrome: the results of the ReFOCUS study. Expert Rev Cardiovasc Ther. 2018;16(7):537–546.
   PubMed Web of Science ®Google Scholar
• Gaudet D, Digenio A, Alexander VJ, et al. The APPROACH study: a randomized, double-blind, placebo-controlled, phase 3 study of volanesorsen administered subcutaneously to patients with familial chylomicronemia syndrome (FCS). J Clin Lipidol. 2017;11(3):814–815.
   Google Scholar
• Inclisiran for Subjects With ACSVD or ACSVD-Risk Equivalents and Elevated Low-density Lipoprotein 232 Cholesterol (ORION-11). ClinicalTrials.gov identifier: NCT03400800. 2018 Apr 26. [cited 2018 Dec 21]. Available from http://clinicaltrials.gov/ct2/show/NCT03400800
   Google Scholar
• Kosmas CE, Muñoz Estrella A, Sourlas A, et al. Inclisiran: a new promising agent in the management of hypercholesterolemia. Diseases. 2018;6(3):63.
   PubMedGoogle Scholar
• Fruchart JC. Pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor alpha modulator for management of atherogenic dyslipidaemia. Cardiovasc Diabetol. 2017;16(1):124.
   PubMedGoogle Scholar
• Ishibashi S, Yamashita S, Arai H, et al. Effects of K-877, a novel selective PPARa modulator (SPPARMa), in dyslipidaemic patients: a randomized, double blind, active- and placebo-controlled, phase 2 trial. Atherosclerosis. 2016;249:36–43.
   PubMed Web of Science ®Google Scholar
• Gaudet D, Gipe DA, Pordy R, et al. ANGPTL3 inhibition in homozygous familial hypercholesterolemia. N Engl J Med. 2017;377:296–297.
   PubMed Web of Science ®Google Scholar
• Graham MJ, Lee RG, Brandt TA, et al. Cardiovascular and metabolic effects of ANGPTL3 antisense oligonucleotides. N Engl J Med. 2017;377:222–232.
   PubMed Web of Science ®Google Scholar
• Hong SJ, Jeong HS, Ahn JC, et al. A phase III, multicenter, randomized, double-blind, active comparator clinical trial to compare the efficacy and safety of combination therapy with ezetimibe and rosuvastatin versus rosuvastatin monotherapy in patients with hypercholesterolemia: I-ROSETTE (Ildong Rosuvastatin & Ezetimibe for Hypercholesterolemia) randomized controlled trial. Clin Ther. 2018;40(2):226–241.
   PubMed Web of Science ®Google Scholar